Drugs & Therapy Perspectives

, Volume 35, Issue 9, pp 424–428 | Cite as

Personalize protocols when deprescribing psychotropics used to manage behavioural changes in individuals with dementia

  • Adis Medical WritersEmail author
Practical Issues and Updates


When managing behavioural changes in individuals with dementia in long-term care settings, non-pharmacological approaches should be the first-line option. However, evidence indicates that psychotropic medications are prescribed excessively in this patient population. Psychotropics can be successfully deprescribed by gradually withdrawing treatment, by taking a person-centred approach that actively involves residents, their family/support persons and multidisciplinary teams, by ensuring healthcare staff are well trained and supported by management, and by employing effective communication strategies.


Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs & Aging (2019) 36(2):125–36 [1] by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.


The preparation of this review was not supported by any external funding.


  1. 1.
    Harrison SL, Cations M, Jessop T, et al. Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia. Drugs Aging. 2019;36(2):125–36.CrossRefGoogle Scholar
  2. 2.
    Westbury J, Gee P, Ling T, et al. More action needed: psychotropic prescribing in Australian residential aged care. Aust N Z J Psychiatry. 2019;53(2):135–47.CrossRefGoogle Scholar
  3. 3.
    Zhao Q-F, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.CrossRefGoogle Scholar
  4. 4.
    Nørgaard A, Jensen-Dahm C, Gasse C, et al. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimers Dis. 2017;56(2):707–16.CrossRefGoogle Scholar
  5. 5.
    Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services United Kingdom Department of Health. London: Department of Health & Social Care; 2009.Google Scholar
  6. 6.
    Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;4:CD007726.Google Scholar
  7. 7.
    Tampi RR, Tampi DJ, Balachandran S, et al. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.CrossRefGoogle Scholar
  8. 8.
    Laver K, Cumming RG, Dyer SM, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016;204(5):191–3.CrossRefGoogle Scholar
  9. 9.
    Buterbaugh WM, Jamrose T, Lazzara J, et al. Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD). Ment Health Clin. 2014;4(4):183–8.CrossRefGoogle Scholar
  10. 10.
    Rosenberg PB, Martin BK, Frangakis C, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.CrossRefGoogle Scholar
  11. 11.
    Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11.CrossRefGoogle Scholar
  12. 12.
    Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pvy055.CrossRefGoogle Scholar
  13. 13.
    Tible OP, Riese F, Savaskan E, et al. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297–309.CrossRefGoogle Scholar
  14. 14.
    Dyer SM, Harrison SL, Laver K, et al. An overview of systematic reviews of pharmacological and nonpharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018;30(3):295–309.CrossRefGoogle Scholar
  15. 15.
    Orgeta V, Qazi A, Spector A, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–8.CrossRefGoogle Scholar
  16. 16.
    Plakiotis C, Bell JS, Jeon YH, et al. Deprescribing psychotropic medications in aged care facilities: the potential role of family members. Adv Exp Med Biol. 2015;821:29–43.CrossRefGoogle Scholar
  17. 17.
    Brodaty H, Aerts L, Harrison F, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600.e7.CrossRefGoogle Scholar
  18. 18.
    Royal Australian & New Zealand College of Psychiatrists. Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia. Melbourne: Royal Australian & New Zealand College of Psychiatrists; 2016.Google Scholar
  19. 19.
    Alldred DP, Kennedy MC, Hughes C, et al. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2:Cd009095.Google Scholar
  20. 20.
    Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756–61.CrossRefGoogle Scholar
  21. 21.
    Jennings AA, Foley T, Walsh KA, et al. General practitioners’ knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: a mixed-methods systematic review. Int J Geriatr Psychiatry. 2018;7(1):62.Google Scholar
  22. 22.
    Chenoweth L, Forbes I, Fleming R, et al. PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia. Int Psychogeriatr. 2014;26(7):1147–60.CrossRefGoogle Scholar
  23. 23.
    Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.CrossRefGoogle Scholar
  24. 24.
    Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.CrossRefGoogle Scholar
  25. 25.
    Turner JP, Edwards S, Stanners M, et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open. 2016;6(3):e009781.CrossRefGoogle Scholar
  26. 26.
    Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.CrossRefGoogle Scholar
  27. 27.
    Rendina N, Brodaty H, Draper B, et al. Substitute consent for nursing home residents prescribed psychotropic medication. Int J Geriatr Psychiatry. 2009;24(3):226–31.CrossRefGoogle Scholar
  28. 28.
    Sawan M, Jeon YH, Fois RA, et al. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Soc Adm Pharm. 2017;13(3):513–23.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations